B of A Securities Rates Tyra Biosciences (TYRA) buy

B of A Securities maintains its buy rating on Tyra Biosciences, setting a $42 price target, a 55.61% upside from the current price.

By TradeTexts Research Desk · Published Jun 13, 2026, 2:08 AM EDT · Updated Jun 15, 2026, 11:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

B of A Securities rated Tyra Biosciences, Inc. ($TYRA) "buy" with a $42 price target on June 10, 2026.

Since the rating, $TYRA is up 14.4% after 1 week, up 28.8% after 1 month and down 27.1% to date (from the $25.42 close on Jun 10, 2026).

TYRA Tyra Biosciences, Inc.

$18.52 -30.87% year to date

Daily close · Oct 16, 2026

Key Points

B of A Securities reiterated its buy rating on Tyra Biosciences, Inc. (TYRA) on June 10, 2026, with a price target of $42.
B of A Securities's $42 price target implies 55.61% upside from Tyra Biosciences, Inc.'s ($TYRA) current $26.99 share price.
Tyra Biosciences, trading at $26.99, has a market cap of approximately $1.61 billion, with a forward P/E ratio indicating it isn't profitable yet.
Insider buying activity was reported on May 28, 2026, with multiple insiders purchasing 13,160 shares each.

Get $TYRA trade alerts by text

We text you when insiders, Congress or big funds trade $TYRA. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Tyra Biosciences, Inc. alert may contain errors. Disclosures

On June 10, 2026, B of A Securities reiterated its buy rating on Tyra Biosciences, Inc. (NasdaqGS: TYRA) with a price target of $42. The stock is currently trading at $26.99.

Other Institutional Activity in Tyra Biosciences

FMR LLC significantly increased its holdings in Tyra Biosciences, adding 7,735,085 shares to reach a total of 7,747,648 shares valued at about $296.7 million. Meanwhile, Janus Henderson Group PLC expanded its position by 955,147 shares, now holding 3,890,589 shares worth approximately $148.9 million. Farallon Capital Management LLC also boosted its investment by 1,514,000 shares, bringing its total to 3,580,818 shares, valued at $137.1 million.

Tyra Biosciences, Inc. Stock Up 4.9%

Shares of NasdaqGS:TYRA traded near $26.99. Tyra Biosciences has a market cap of approximately $1.61 billion. The stock has a 52-week low of $8.98 and a high of $40.65, with a 50-day moving average of $33.63 and a 200-day moving average of $25.86. Its current ratio of 20.49 and quick ratio of 20.05 suggest strong liquidity, while a debt-to-equity ratio of 1.47 indicates manageable leverage.

12-month forecast

$TYRA price target

Tyra Biosciences, Inc. daily closes and this analyst's $42 target. Not advice.

Insider Buying and Selling at Tyra Biosciences, Inc.

Several insiders, including Susan Moran, Jake Simson, Adele Gulfo, and Robert More, each purchased 13,160 shares on May 28, 2026. These transactions were not part of any pre-planned trading program.

Analysts Set New Price Targets

On June 10, 2026, B of A Securities maintained its buy rating on Tyra Biosciences with a $42 price target. Guggenheim initiated coverage with a buy rating and a $54 target on April 15, 2026. Canaccord Genuity also initiated coverage with a buy rating and a $50 target on April 6, 2026. The consensus among analysts is a strong buy, with a mean price target of $51.60 across 11 opinions.

About Tyra Biosciences

Tyra Biosciences, Inc. is a biotechnology company based in Carlsbad, California. It focuses on developing precision medicines for diseases related to fibroblast growth factor receptor (FGFR) biology. The company uses its SNÅP platform to design drugs for oncology and genetically defined conditions. Tyra's lead product, FGFR3, is in trials for metastatic urothelial carcinoma. Other products in development include TYRA-300 for skeletal conditions and TYRA-200 for intrahepatic cholangiocarcinoma.

Bottom Line

Tyra Biosciences continues to attract attention from analysts and investors. B of A Securities' reiterated buy rating and $42 price target reflect confidence in the company's prospects. With significant insider buying and strong institutional interest, Tyra remains a company to watch. Investors should note that 13F filings are historical and may not reflect current positions.